Using an intracranial injection model for RET fusion-positive NSCLC brain metastasis in immunodeficient mice, it was reported that either Ponatinib (anti-BCR-ABL) or Selpercatinib treatment via intracranial administration significantly reduced tumor size. This evidence concerns the gene RET and neoplasm.